Clinical trials information on virus proteome based vaccine design

This page provides additional information to users of the VLCvirus on clinical trial where oncogenic virusess are used, either in live/attenuated/ or in combination with chemotherapy for treatment of lung cancer. By clicking onto clinical trial ID (NCTXXXXX), user will be redirected towards clinical trial page containing all the information regarding disease condition, status etc. For more information see HELP page.

Lung Cancer Vaccine Plus Oral Dietary Supplement vaccine 1650-G NCT01829373
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer autologous dendritic cell cancer vaccine NCT00103116
Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer Vaccine Treatment|Drug: Cyclophosphamide|Drug: All-trans retinoic acid (ATRA)NCT00601796
Vaccine Therapy in Treating Patients With Stage III, Stage IV, or Relapsed Non-Small Cell Lung Cancer Treated With First-Line Chemotherapy Ad100-gp96Ig-HLA A1NCT00503568
Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung CancerAutologous dendritic cell-adenovirus p53 vaccine|Drug: Carboplatin|Drug: EtoposideNCT00049218
Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated Polysialic Acidvaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvantNCT01349647
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung CancerDRibble vaccineNCT00850785
Safety and Efficacy of Mix Vaccine in Lung Carcinoma PatientMV mix vaccine|Other: standard treatmentNCT02333474
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancermutant p53 peptide pulsed dendritic cell vaccine|Procedure: adjuvant therapyNCT00019929
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancermutant p53 peptide pulsed dendritic cell vaccine|Procedure: adjuvant therapyNCT00019929